Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML)

John F. DiPersio, Guenther Koehne, Nirali N. Shah, Lea Bernard, Hyung C Suh, Divya Koura, Miguel Angel Perales, Roni Tamari, Muhammad Umair Mushtaq, Joseph E. Maakaron, Michael R. Loken, Darren A Stanizzi, Melissa M. Lee-Sundlov, Sanjana Thosar, Sharon L Hyzy, Glen D Raffel, Brenda W Cooper

Blood (2024) 144 (Supplement 1): 2873.

https://doi.org/10.1182/blood-2024-205641

Published: 2024

Journal Articles

Potential Role of Donor CD3 Chimerism in Predicting Relapse after Allogeneic Transplantation in Patients with Acute Myelogenous Leukemia (AML)

Maciej Kabat, Vanisha Patel, Sukhdeep Kaur, Michael Pelliccia, Charles Zhao, Patrick Roney, Alexandra Della Pia, Jaeil Ahn, David H. Vesole, Michele L. Donato, Hyung C Suh, Christina Cho, Pritish K. Bhattacharyya, Scott D Rowley, Andrew Ip

Blood (2024) 144 (Supplement 1): 7413.

https://doi.org/10.1182/blood-2024-204093

Published: 2024

Journal Articles

TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic HCT with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial

Blood (2024) 144 (Supplement 1): 924.

https://doi.org/10.1182/blood-2024-201526

Published: 2024

Journal Articles

Dynamic Changes in Pre- and 3 Months Post-Transplant NGS MRD Status May Predict the Allogeneic Stem Cell Transplant Outcome of Patients with AML

Hyung C Suh, Amy Einstein, Addi Georgantzis, Phyllis McKiernan, Melissa Baker, Michele S Boonstra, Sukhdeep Kaur, Christina Cho, Scott D Rowley, Michele L. Donato

Blood (2023) 142 (Supplement 1): 2238.

https://doi.org/10.1182/blood-2023-185243

Published: 2023

Journal Articles

Fluoroquinolone-Resistant Enterobacteriaceae Prevalence for Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation (aHSCT) in the Treatment of Multiple Myeloma (MM)

Elizabeth Titova, Scott Rowley, Barry Kreiswirth, Melissa Baker, Eliana Baker, Christina Cho, Anne S. Renteria, Alaa Ali, Pashna N. Munshi, Sukhdeep Kaur, Michele L. Donato, Chiranjeev Dash, Hyung C Suh, Kelly K. Yen, Austin J. Terlecky

Blood (2023) 142 (Supplement 1): 2223.

https://doi.org/10.1182/blood-2023-174405

Published: 2023

Journal Articles

Comparison of Fludarabine/Cyclophosphamide Vs Bendamustine As Lymphodepleting Regimen for CAR-T: A Safety and Efficacy Analysis in Patients with Relapsed/ Refractory Multiple Myeloma

Sarvarinder Kaur Gill, Noa Biran, Pooja Phull, Sukhdeep Kaur, Hyung C Suh, Christina Cho, Michele L. Donato, Scott D Rowley, David H. Vesole, David S. Siegel, Harsh Parmar

Blood (2023) 142 (Supplement 1): 6903.

https://doi.org/10.1182/blood-2023-190507

Published: 2023

Journal Articles

Graft-Versus-Host Disease (GvHD) Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation (haplo-PBSCT) Using Abatacept in Combination with Post-Transplant Cyclophosphamide (PTCy)

Sukhdeep Kaur, Simon Gelman, Scott Rowley, Eliana Baker, Melissa Baker, Hyung C Suh, Christina Cho, Michele L. Donato

Blood (2023) 142 (Supplement 1): 6996.

https://doi.org/10.1182/blood-2023-184901

Published: 2023

Journal Articles

Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT)

John DiPersio, Brenda W Cooper, Hyung C Suh, Divya Koura, Lea Bernard, Nirali N. Shah, Roland B. Walter, Miguel-Angel Perales, Markus Mapara, Roni Tamari, Michael R. Loken, Kyle Breitschwerdt, Sritama Nath, Glen D Raffel, Guenther Koehne

Blood (2023) 142 (Supplement 1): 483.

https://doi.org/10.1182/blood-2023-190037

Published: 2023

Journal Articles

Comparison of Bendamustine Versus Fludarabine/ Cyclophosphamide Lymphodepletion in Adult Patients Receiving CD19 CAR-T Cell Therapy

Blood (2023) 142 (Supplement 1): 3510.

https://doi.org/10.1182/blood-2023-189349

Published: 2023

Journal Articles

Comparison of Non-Myeloablative Conditioning Regimens Flu/Bu2, Flu/Mel 100 and Flu/TBI in Patients with AML and MDS

Phyllis McKiernan, Simon Gelman, Scott D Rowley, Sukhdeep Kaur, Christina Cho, Hyung C Suh, Michele S Boonstra, Addi Georgantzis, Melissa Baker, Amy Einstein, Michele L. Donato

Blood (2023) 142 (Supplement 1): 6961.

https://doi.org/10.1182/blood-2023-187812

Published: 2023

Journal Articles

Trial in Progress: An Open-Label, Multi-Center Phase 2 Study to Assess the Safety and Efficacy of Burixafor (GPC-100) and Propranolol with and without G-CSF for the Mobilization of Stem Cells in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplant

Nina Caculitan, Josephine M. Cardarelli, Jack Khouri, Hyung C Suh, Muthalagu Ramanathan, Ann Woolfrey

Blood (2023) 142 (Supplement 1): 7082.

https://doi.org/10.1182/blood-2023-187191

Published: 2023

Journal Articles

Using Targeted Transcriptome and Machine Learning of Pre- and Post-Transplant Bone Marrow Samples to Predict Acute Gvhd (aGVHD) and Overall Survival after Allogeneic HSC Transplantation

Maher Albitar, Hong Zhang, Andrew L. Pecora, Andrew Ip, Andre H. Goy, Spiraggelos Antzoulatos, Wanlong Ma, Sukhdeep Kaur, Hyung C. Suh, Michele L. Donato, Scott D. Rowley

Blood (2022) 140 (Supplement 1): 4757–4758.

https://doi.org/10.1182/blood-2022-162816

Published: 2022

Journal Articles

Effect of Daratumumab on Stem Cell Mobilization and Engraftment Kinetics Post Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma

Samir Oza, Ronit Slotky, Pranay Vissa, Pooja Phull, Sukhdeep Kaur, Hyung C. Suh, Michele L. Donato, Scott D. Rowley, Noa Biran, David H. Vesole, David Siegel, Harsh Parmar

Blood (2022) 140 (Supplement 1): 10441–10442.

https://doi.org/10.1182/blood-2022-171098

Published: 2022

Journal Articles

Trial in Progress: A First-in-Human Phase 1/2 Study of Hematopoietic Stem Cell Transplantation (HCT) with VOR33 (CD33-Deleted Allograft) Followed By Treatment with Gemtuzumab Ozogamicin (GO) in Patients with CD33+ Acute Myeloid Leukemia (AML) Who Are at High-Risk of Post-HCT Relapse

Brenda W. Cooper, Hyung C. Suh, Divya Koura, Guenther Koehne, Christina Cho, Nadia M. Bambace, Léa Bernard, Nirali N. Shah, Roland B. Walter, John F. DiPersio, Sritama Nath, Melissa M. Lee-Sundlov, Ali Lacy, Darren Stanizzi, Karen Kuhn, Jennifer S. Whangbo, Christopher Slapak, Glen D. Raffel

Blood (2022) 140 (Supplement 1): 12973–12975.

https://doi.org/10.1182/blood-2022-165289

Published: 2022

Journal Articles

Trial in Progress: A Phase 1 Umbrella Study of TCR-Engineered T Cells That Target HA-1 (TSC-100) and HA-2 (TSC-101) to Treat Residual Leukemia after Hematopoietic Cell Transplantation

Ran Reshef, Hyung C. Suh, Monzr M. Al Malki, Aasiya Matin, Ashish S Kothari, Allison Bell, Antoine J Boudot, Yun Wang, Nina Abelowitz, James Murray, Gavin Macbeath, Debora Barton, Shrikanta Chattopadhyay

Blood (2022) 140 (Supplement 1): 7468–7469.

https://doi.org/10.1182/blood-2022-167707

Published: 2022

Journal Articles

Reliability of Liquid Biopsy and Next Generation Sequencing in Monitoring Residual Disease Post-Hematopoietic Stem Cell Transplant

Maher Albitar, Hong Zhang, Andrew L. Pecora, Andrew Ip, Andre H. Goy, Jeffrey Justin Estella, Ivan De Dios, Wanlong Ma, Sukhdeep Kaur, Hyung C. Suh, Michele L. Donato, Scott D. Rowley

Blood (2021) 138 (Supplement 1): 1828.

https://doi.org/10.1182/blood-2021-147414

Published: 2021

Journal Articles

Assessment of Serology after Sars-Cov-2 Vaccine in Allogeneic HCT Recipients

Melissa Baker, Maria Cortes, Jaeil Ahn, Michele L. Donato, Sukhdeep Kaur, Hyung C. Suh, Alison Morawski, Phyllis McKiernan, Amy Einstein, Michele Boonstra, Scott D. Rowley

Blood (2021) 138 (Supplement 1): 2900.

https://doi.org/10.1182/blood-2021-145642

Published: 2021

Journal Articles

Bone Marrow-Based Biomarkers for Predicting aGVHD Using Targeted RNA Next Generation Sequencing and Machine Learning

Maher Albitar, Hong Zhang, Andrew L. Pecora, Andrew Ip, Andre H. Goy, Spiraggelos Antzoulatos, Ivan De Dios, Wanlong Ma, Sukhdeep Kaur, Hyung C. Suh, Michele L. Donato, Scott D. Rowley

Blood (2021) 138 (Supplement 1): 2892.

https://doi.org/10.1182/blood-2021-147583

Published: 2021

Journal Articles

Prospective Randomized Comparative Study of Myeloablative Fludarabine/Busulfan (Flu/Bu4) and Fludarabine/Busulfan/Total Body Irradiation (Flu/Bu4/TBI) Conditioning Regimen for Patients with Myeloid Diseases

Hyung C. Suh, MDPhD, Scott D. Rowley, MD, Sukhdeep Kaur, MD, Brittany Lukasik, Phyllis McKiernan, Michele Boonstra, APN, Milissa Baker, MSN, ANP, Mary E Dilorenzo, APN, Alan Skarbnik, MD, Themba Nyirenda, PhD, David H. Vesole, MD PhD, Michele L. Donato, MD

Blood (2020) 136 (Supplement 1): 9.

https://doi.org/10.1182/blood-2020-142272

Published: 2020

Journal Articles

Bioengineered Autologous Dendritic Cells Enhance CAR T Cell Cytotoxicity By Providing Cytokine Stimulation and Intratumoral Dendritic Cells

Hyung C Suh, MD PhD, Katherine A. Pohl, B.S., Christina Termini, PhD BS, Jenny Kan, BS, John M. Timmerman, MD, Dennis J. Slamon, MD PhD, John P Chute, MD

Blood (2018) 132 (Supplement 1): 3693.

https://doi.org/10.1182/blood-2018-99-115296

Published: 2018

NARROW

A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML)

Potential Role of Donor CD3 Chimerism in Predicting Relapse after Allogeneic Transplantation in Patients with Acute Myelogenous Leukemia (AML)

TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic HCT with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial

Dynamic Changes in Pre- and 3 Months Post-Transplant NGS MRD Status May Predict the Allogeneic Stem Cell Transplant Outcome of Patients with AML

Fluoroquinolone-Resistant Enterobacteriaceae Prevalence for Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation (aHSCT) in the Treatment of Multiple Myeloma (MM)

Comparison of Fludarabine/Cyclophosphamide Vs Bendamustine As Lymphodepleting Regimen for CAR-T: A Safety and Efficacy Analysis in Patients with Relapsed/ Refractory Multiple Myeloma

Graft-Versus-Host Disease (GvHD) Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation (haplo-PBSCT) Using Abatacept in Combination with Post-Transplant Cyclophosphamide (PTCy)

Comparison of Bendamustine Versus Fludarabine/ Cyclophosphamide Lymphodepletion in Adult Patients Receiving CD19 CAR-T Cell Therapy

Comparison of Non-Myeloablative Conditioning Regimens Flu/Bu2, Flu/Mel 100 and Flu/TBI in Patients with AML and MDS

Trial in Progress: An Open-Label, Multi-Center Phase 2 Study to Assess the Safety and Efficacy of Burixafor (GPC-100) and Propranolol with and without G-CSF for the Mobilization of Stem Cells in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplant

Using Targeted Transcriptome and Machine Learning of Pre- and Post-Transplant Bone Marrow Samples to Predict Acute Gvhd (aGVHD) and Overall Survival after Allogeneic HSC Transplantation

Effect of Daratumumab on Stem Cell Mobilization and Engraftment Kinetics Post Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma

Trial in Progress: A First-in-Human Phase 1/2 Study of Hematopoietic Stem Cell Transplantation (HCT) with VOR33 (CD33-Deleted Allograft) Followed By Treatment with Gemtuzumab Ozogamicin (GO) in Patients with CD33+ Acute Myeloid Leukemia (AML) Who Are at High-Risk of Post-HCT Relapse

Trial in Progress: A Phase 1 Umbrella Study of TCR-Engineered T Cells That Target HA-1 (TSC-100) and HA-2 (TSC-101) to Treat Residual Leukemia after Hematopoietic Cell Transplantation

Reliability of Liquid Biopsy and Next Generation Sequencing in Monitoring Residual Disease Post-Hematopoietic Stem Cell Transplant

Assessment of Serology after Sars-Cov-2 Vaccine in Allogeneic HCT Recipients

Bone Marrow-Based Biomarkers for Predicting aGVHD Using Targeted RNA Next Generation Sequencing and Machine Learning

Prospective Randomized Comparative Study of Myeloablative Fludarabine/Busulfan (Flu/Bu4) and Fludarabine/Busulfan/Total Body Irradiation (Flu/Bu4/TBI) Conditioning Regimen for Patients with Myeloid Diseases

Bioengineered Autologous Dendritic Cells Enhance CAR T Cell Cytotoxicity By Providing Cytokine Stimulation and Intratumoral Dendritic Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only